57 results
6-K
EX-99.2
AMYT
Amryt Pharma Plc
11 May 22
Current report (foreign)
4:30pm
Securities
Our investments primarily consist of commercial paper and corporate and government debt securities. These marketable securities are classified … , on a first-in, first-out basis. Inventories that may be used for either research and development or commercial sale are classified as inventory until
6-K
EX-99.1
AMYT
Amryt Pharma Plc
29 Oct 20
Amryt Announces Positive Results from Phase 3 Trial of Filsuvez® In Epidermolysis Bullosa
8:00am
were classified as ‘moderate’ and 1 ‘severe’. The single target wound infection reported in the Oleogel-S10 group was classified as ‘mild’.
In patients
6-K
EX-99.1
AMYT
Amryt Pharma Plc
6 Aug 21
Amryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
8:18am
, it is classified as a subsidiary. The Company controls an investee if all three of the following elements are present: power over an investee … on fair value as at September 24, 2019. The CVRs have been classified as a financial liability in the Condensed Consolidated Statement of Financial
UPLOAD
AMYT
Amryt Pharma Plc
19 Mar 20
Letter from SEC
12:00am
of costs classified
as research and development for each period presented.
Intellectual Property, page 90
8. Please revise this section
6-K
EX-99.1
AMYT
Amryt Pharma Plc
5 May 21
Amryt Reports Record Q1 2021 Financial and Operating Results
9:40am
ended March 31, 2021. Subsidiaries are entities controlled by the Company. Where the Company has control over an investee, it is classified … on the successful completion of the acquisition and, accordingly, have been based on fair value as at September 24, 2019. The CVRs have been classified
6-K
EX-99.1
hkh65g
4 Mar 21
Amryt Announces Record FY 2020 Results
8:20am
6-K
EX-99.1
s9pvow
6 Aug 20
Amryt Announces Q2 2020 Results and Issues Positive Revenue Guidance for Fy 2020
9:43am
424B3
1xmcza7esvvhjyqi
6 Aug 21
Prospectus supplement
8:17am
424B3
f1oo at1gkoefdtc5ntl
4 Mar 21
Prospectus supplement
8:38am
424B3
6xrgm0v n3
6 Aug 21
Prospectus supplement
8:18am
424B3
lhz7 qolu
2 Jun 21
Prospectus supplement
10:08am
424B3
drrk z5sju3y8
3 Nov 21
Prospectus supplement
7:32am
6-K
EX-99.1
st9ofy3jpps
3 Nov 21
Amryt Reports Strong Q3 2021 Results
7:31am
6-K
EX-99.5
khnn2fq
4 Aug 22
Results of Annual General Meeting
7:38am
424B3
7gyr4ft51lou
3 Nov 21
Prospectus supplement
7:33am
6-K
EX-99.1
klwf8k4686auqcq
4 May 22
Amryt Reports Record Q1 2022 Results
7:43am
6-K
EX-99.1
kedfo0dkhcl5 f79ker6
5 Nov 20
Amryt Reports Record Q3 2020 Results - Raising FY 2020 Revenue Guidance
7:55am
DRSLTR
011s60b8 5tv7
28 May 20
Correspondence regarding draft registration statement
12:00am
424B3
4556llmpc0
9 Mar 22
Prospectus supplement
9:25am
424B3
dlmoyhd8c1
4 May 22
Prospectus supplement
7:45am